Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pharmacokinetics, safety, and tolerability of cefiderocol in hospitalized neonates and young infants
TCTR20240718005Phase 2Not yet recruiting
- Sponsor
- Shionogi & Co., Ltd.
- Start
- Nov 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of cefiderocol in Gram-negative bacterial infection, sponsored by Shionogi & Co., Ltd.. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
cefiderocol
03
Conditions
Gram-negative bacterial infection
Beyond the preview
Go deeper on TCTR20240718005.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on TCTR20240718005.